Impact of inflammation and steroids on anti-coagulation in children supported on a ventricular assist device
Brandewie K, Lorts A, Luchtman-Jones L, Gao Z, Geer B, Villa C, Perry T (2024) · Journal of Artificial Organs · n=10
Study Profile
- Design
- single-center retrospective review of pediatric VAD patients <3 years anticoagulated with bivalirudin (Cincinnati Children's Hospital, October 2020-May 2022)
- Sample size (n)
- 10
- Intervention
- Bivalirudin anticoagulation with dual aPTT and dilute thrombin time (dTT) monitoring during inflammatory and steroid events
- Comparator
- Same patients' baseline (non-inflammatory) anticoagulation monitoring patterns
- Primary endpoint
- Correlation between aPTT and dTT during 16 infection/inflammation events, 3 chylothorax events, and 6 steroid events
- Primary result
- Inflammation/infection significantly decreased correlation between dTT and aPTT; dTT increased prior to inflammation/infection while aPTT remained unchanged; dTT more accurately reflected steroid-mediated anticoagulation stabilization
- Follow-up duration
- VAD support duration (~19 months observational window)
- PMID
- 38581568
Key Findings
- Inflammation/infection decouple aPTT and dTT correlation
- dTT increases before clinical inflammation diagnosis
- Steroids stabilize anticoagulation, better reflected by dTT than aPTT
- 16 inflammation, 3 chylothorax, 6 steroid events analyzed
- Supports protocol shift from aPTT to dTT monitoring
Limitations
- Very small cohort (n=10)
- Single-center retrospective design
- Children <3 years - limited generalizability to older children
- No clinical outcome correlation
- Not applicable to whole-leech hirudotherapy
Clinical Implications
Brandewie 2024 refines the safety monitoring framework for bivalirudin in pediatric VAD by demonstrating context-dependent aPTT reliability. For ASH, the study illustrates the granular pharmacovigilance infrastructure that the synthetic thrombin inhibitor pharmaceutical pathway requires, distinct from the much simpler clinical monitoring (visible bleeding, hemoglobin) that suffices for device-leech K040187 US clinical practice.
Related Trials
Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation
McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024)
Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support
Trigonis R, Smith N, Porter S, Anderson E, Jennings M, Kapoor R, Hage C, Moiz S, Garcia J, Rahman O (2021)
Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation
Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022)
Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review
Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, Jeng EI, Peek GJ (2023)